VX-770 — Competitive Intelligence Brief

VX-770 (VX-770) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR potentiator. Area: Respiratory / Genetic Disorders.

phase 3 CFTR potentiator CFTR (cystic fibrosis transmembrane conductance regulator) Respiratory / Genetic Disorders Small molecule

Target snapshot

VX-770 (VX-770) — Vertex Pharmaceuticals Incorporated. VX-770 is a CFTR potentiator that increases the opening probability and duration of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel at the cell surface.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VX-770 TARGET	VX-770	Vertex Pharmaceuticals Incorporated	phase 3	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)
SUZ	SUZ	Vertex Pharmaceuticals Incorporated	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)
IVA	IVA	Vertex Pharmaceuticals Incorporated	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)
Ivacaftor (VX-770)	Ivacaftor (VX-770)	University of Alabama at Birmingham	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CFTR potentiator class)

1. Vertex Pharmaceuticals Incorporated · 4 drugs in this class
2. Jennifer Taylor-Cousar · 1 drug in this class
3. University of Alabama at Birmingham · 1 drug in this class